SCHEMBL7636331

SCHEMBL7636331

NCCNP(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.42
CYP3A4 P08684 4/20 0.36
TDP1 Q9NUW8 2/20 0.36
TAAR1 Q96RJ0 3/20 0.36
LOXL2 Q9Y4K0 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP2A6 P11509 1/20 0.36
HTR2A P28223 1/20 0.36
CA12 O43570 1/20 0.34
CA3 P07451 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
CA5B Q9Y2D0 1/20 0.34
TSHR P16473 4/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzaldehyde SCHEMBL28728959 0.86 ALDH1A1 (0.47) KIF11CYP2A6ALDH1A1KMT2AMAOA
SCHEMBL4203004 0.85 CYP3A4 (0.43) CYP3A4TDP1TAAR1SMN1; SMN2TSHR
SCHEMBL9907211 0.77 POLB (0.41) CYP3A4TDP1SMN1; SMN2TSHRALDH1A1
SCHEMBL17201445 0.77 SIGMAR1 (0.38) CYP3A4TDP1TAAR1CA12CA9
SCHEMBL28580058 0.76 NPC1 (0.50) CYP3A4TAAR1SMN1; SMN2CA12CA9
SCHEMBL30359275 0.74 ALDH1A1 (0.42) CA12CA9TSHRALDH1A1KDM4E
SCHEMBL2155415 0.73 KCNN4 (0.44) CYP3A4TDP1SMN1; SMN2TSHRALDH1A1
SCHEMBL9907231 0.72 TAAR1 (0.42) TAAR1HTR2ARAB9AMEN1KMT2A
SCHEMBL321882 0.72 TDP1 (0.50) CYP3A4TDP1CA12CA3CA4
SCHEMBL9288104 0.69 TDP1 (0.47) CYP3A4TDP1TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563073-A For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds 诺罗利西斯公司 2019-04-02 CN disclosed
CN-101027278-A Preparation of beta-amino acids having affinity for the alpha-2-delta protein WARNER LAMBERT CO (US) 2007-08-29 CN disclosed
US-20020058832-A1 Novel olefination process to itaconate and succinate derivatives PFIZER INC. 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058832-A1 Novel olefination process to itaconate and succinate derivatives HOGA1, HADHA, OGDH KIF11 1867/4885CYP3A4 219/4885TDP1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.